The relevance of IL‐6 in COVID‐19‐associated ARDS was recently shown in an open‐label study where blockade with tocilizumab, an IL‐6R antibody, resulted in a rapid recovery of peripheral oxygen saturation and recovery from febrile signs and symptoms (Xu et al, 2020). Here, IL6R is linked to COVID-19.